AbbVie Inc. (ABBV) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $210.32. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ABBV = $119.91 (-43% from the current price, the stock appears overvalued). Analyst consensus target is ABBV = $256 (+21.8% upside).
Valuation: ABBV trades at a trailing Price-to-Earnings (P/E) of 88.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 7.69.
Financials: revenue is $61.2B, +1.9%/yr average growth. Net income is $4.2B, growing at -24.1%/yr. Net profit margin is 6.9% (thin). Gross margin is 83.7% (+13.7 pp trend).
Balance sheet: total debt is $69.1B with negative equity of -$3.3B — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.67 (tight liquidity). Debt-to-assets is 51.6%. Total assets: $134.0B.
Analyst outlook: 27 / 40 analysts rate ABBV as buy (68%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 38/100 (Fail), Growth 30/100 (Fail), Past 100/100 (Pass), Health 50/100 (Partial), Moat 94/100 (Pass), Future 67/100 (Pass), Income 45/100 (Partial).
